Fundz

Travere Therapeutics

San Diego, California, United States · Biotechnology, Health Care, Pharmaceutical

Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for people living with rare diseases. It specializes in addressing unmet medical needs associated with kidney diseases. The company aims to improve treatment outcomes for patients through scientific advancements and breakthroughs in drug development.

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Headquarters
San Diego, California, United States
Employees
550
Industries
Biotechnology, Health Care, Pharmaceutical
Status
Public (TVTX)
Website
travere.com
LinkedIn
Company page

Recent activity at Travere Therapeutics

  • : Travere Therapeutics Appoints Bradley L. Campbell as Chief Executive Officer
  • : SEC 8-K (5.02): On September 21, 2026, Travere Therapeutics, Inc. announced the planned departure of Dr. Eric Dube as President and CEO, effective December 1, 2026. Dr. Dube will also step down from the Board of Directors but will remain as an Executive Advisor until February 15, 2027, to ensure a smooth transition. Bradley L. Campbell has been appointed as his successor, effective on the same date. Mr. Campbell brings over 25 years of biopharmaceutical experience, previously serving as CEO of Amicus Therapeutics until its acquisition in April 2026. This transition may impact the strategic direction of the company as new leadership is introduced.
  • : SEC 8-K (5.02): On July 6, 2026, Sandra Calvin, the chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, announced her intention to retire, with the expected date being following the filing of the Company’s Annual Report on Form 10-K in February 2027. John Torell, currently the Vice President and Controller, is anticipated to succeed Ms. Calvin. The Board plans to appoint Mr. Torell to these roles prior to the Retirement Date to ensure a smooth transition of responsibilities. Mr. Torell, a Chartered Financial Analyst and Certified Public Accountant, has extensive experience in various financial roles, enhancing the Company's leadership continuity in accounting operations and financial reporting.

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Employee benefit plans

Travere Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

About Travere Therapeutics: questions and answers

What does Travere Therapeutics do?

Travere Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for people living with rare diseases. It specializes in addressing unmet medical needs associated with kidney diseases. The company aims to improve treatment outcomes for patients through scientific advancements and breakthroughs in drug development.

Where is Travere Therapeutics headquartered?

Travere Therapeutics is headquartered in San Diego, California, United States.

How many employees does Travere Therapeutics have?

Travere Therapeutics has about 550 employees.

What is the latest news on Travere Therapeutics?

On Sep 21, 2026, Travere Therapeutics Appoints Bradley L. Campbell as Chief Executive Officer

Is Travere Therapeutics a public company?

Yes. Travere Therapeutics is publicly traded under the ticker TVTX.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Travere Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.